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A randomized, controlled, open-label, parallel-group, single-center study to determine biomarkers of
exposure to nine selected harmful and potentially harmful constituents (HPHC) in cigarette smoke and
urinary excretion of mutagenic material in 160 male and female subjects smoking Marlboro cigarettes
(6 mg tar, 0.5 mg nicotine, and 7.0 mg CO) at baseline. Subjects were randomized to continue smoking
Marlboro cigarettes, or switch to using an Electrically Heated Cigarette Smoking System (EHCSS) smoking
one of two EHCSS series-K cigarettes, the EHCSS-K6 cigarette (5 mg tar, 0.3 mg nicotine, and 0.6 mg CO)
or the EHCSS-K3 cigarette (3 mg tar, 0.2 mg nicotine, and 0.6 mg CO), or switch to smoking Philip Morris
One cigarettes (1 mg tar, 0.1 mg nicotine, and 2.0 mg CO), or to no-smoking. The mean decreases from
baseline to Day 8 were statistically signiﬁcant (p 6 0.05) for all determined HPHC including benzene
and CO (the primary objectives), and urinary excretion of mutagenic material in the EHCSS-K6 (range
35.5 ± 29.2% to 79.4 ± 14.6% [mean ± standard deviation]), EHCSS-K3 (range 41.2 ± 26.6% to
83.1 ± 9.2%), and PM1 (range 14.6 ± 24.1% to 39.4 ± 17.5%) groups. The largest reductions in expo-
sure occurred in the no-smoking group (range 55.4 ± 45.0% to 100.0 ± 0.0%).
 2012 Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction
There is overwhelming medical and scientiﬁc consensus that
cigarette smoking causes lung cancer, heart disease, emphysema,
and other serious diseases in smokers (US Department of Health
and Human Services, 2010). In the US, the Family Smoking Preven-
tion and Tobacco Control Act (FSPTCA) (Family Smoking Prevention
and Tobacco Control Act, 2009) has empowered the Food and Drug
Administration (FDA) to evaluate and regulate modiﬁed risk tobac-
co products (MRTPs) (Deyton et al., 2010). The FDA, in consultation
with the Institute of Medicine (IOM), has also been charged to issue
guidance and regulations on the scientiﬁc evidence required for
the assessment and ongoing review of MRTPs (Food and Drug
Administration, 2012; Institute of Medicine, 2012).
The Electrically Heated Cigarette Smoking System (EHCSS) with
the specially developed EHCSS cigarette has reduced levels of a
wide range of toxicologically important cigarette smoke HPHC
resulting in signiﬁcantly lowered biological activity of mainstream
smoke compared to conventional lit-end cigarettes in laboratory-
based test systems (Werley et al., 2008; Zenzen et al., 2012). The
third-generation EHCSS series-K puff-activated electrical heatericker).
-NC-ND license.can be used to smoke either non-menthol or menthol EHCSS ser-
ies-K cigarettes. Two versions of the EHCSS series-K non-menthol
cigarette are available which differ only in the construction of
the ﬁlter. A more efﬁcient ﬁlter is used in the EHCSS-K3 cigarette
resulting in reduced delivery of cigarette smoke HPHC compared
to the EHCSS-K6 cigarette when tested according to International
Organization for Standardization (ISO) methods. The EHCSS heater
cannot be used to smoke conventional lit-end cigarettes.
The current communication, the ﬁrst in a series of ﬁve clinical
evaluations describing data from investigations performed under
both controlled (Tricker et al., 2012a,b,c) and real-life smoking con-
ditions (Martin Leroy et al., 2012), reports a randomized, con-
trolled, open-label, parallel-group, single-center study to
compare biomarkers of exposure to selected cigarette smoke HPHC
and excretion of mutagenic material in urine between two EHCSS
cigarettes and two conventional cigarettes. Subjects normally
smoking the Marlboro non-menthol cigarette (M6UK) were ran-
domized into one of the ﬁve following groups: subjects either con-
tinued smoking the M6UK cigarette, or switched to smoke either
the EHCSS-K3 or the EHCSS-K6 cigarette, or switched to smoke
the Philip Morris One cigarette (PM1), or to no-smoking, for a dura-
tion of 8 days. The study was designed to examine changes in se-
lected tobacco-speciﬁc and tobacco-related biomarkers of
exposure to HPHC present in the gas–vapor phase (1,3-butadiene,
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phase (NNK, nicotine, pyrene, and o-toluidine) of mainstream cig-
arette smoke.
The primary objectives of the study was to compare exposure to
CO, determined as carboxyhemoglobin concentration in blood at
17:00 h (COHb17:00), and benzene, assessed as urinary excretion
of S-phenyl mercapturic acid (S-PMA), between the study groups
on Day 8. Exposure to CO and benzene were selected as the pri-
mary objectives of the study based on the reduction of both HPHC
in mainstream smoke of the EHCSS compared to conventional cig-
arettes (Werley et al., 2008; Zenzen et al., 2012) and the previous
observations that COHb and excretion of S-PMA are reduced in
smokers after switching to the EHCSS (Frost-Pineda et al., 2008a,b).2. Materials and methods
2.1. Subjects
Adult male and female smokers (19–50 years of age) with
acceptable health conditions who had smoked 10–25 cigarettes
per day (CPD) and the Marlboro non-menthol cigarette (6 mg tar,
0.5 mg nicotine, and 7.0 mg CO) as their exclusive brand for at least
4 weeks prior to screening were recruited. All subjects provided a
signed informed consent prior to screening procedures. Subjects
were compensated for study participation and were free to with-
draw from the study at any time. Screening was performed within
4 weeks prior to in-clinic study conﬁnement and included medical
history, physical examination, vital signs, electrocardiogram (ECG),
pulmonary function tests, clinical laboratory tests, and the Fag-
erström Test for Nicotine Dependence (FTND) (Heatherton et al.,
1991). Women of childbearing potential who used a reliable meth-
od of contraception were considered as eligible for study inclusion;
pregnant or lactating women were excluded. Other exclusion crite-
ria included presence of a clinically signiﬁcant disease, alcohol or
drug abuse, <2% COHb (suggestive of being a non-smoker),
<12.5 g/dl hemoglobin or <38% hematocrit, a positive test for hu-
man immunodeﬁciency virus (HIV) or hepatitis, and use of a nico-
tine-containing product other than cigarettes within 3 months
prior to screening. The use of any medication with the exceptions
of hormonal contraceptives for female subjects and occasional use
of paracetamol (up to 1 g/day) to treat headache was prohibited in
the week before the study.EHCSS-K6 (N= 32) 
M6UK 
(N = 160) 
Subject  
recruitment 
and 
medical  
screening 
Controlled smoking (9 days) 
EHCSS-K3 (N= 32) 
M6UK (N= 32) 
PM1 (N = 32) 
No-smoking (N = 32) 
Day 0 Days 1 to 8 
Biomarker assessments (blood and 24-h urine) 
Fig. 1. Schedule of study events. Footnote: on Day 0 (baseline) all subjects smoked
the M6UK cigarette prior to randomization into the ﬁve study groups. All cigarettes
described in Table 2.2.2. Cigarette products
Conventional cigarette (CC) brands were selected to include a
leading market share cigarette of similar ISO tar and nicotine yields
to the EHCSS-K6 and a representative CC with a low ISO tar and
nicotine yield. The cigarettes also had a similar tobacco blend to
that used in the EHCSS test cigarettes. Study cigarettes were ana-
lyzed for tar and nicotine according to ISO methods. All study cig-
arettes were conditioned according to ISO standard 3402
(International Organization for Standardization, 1991). Conven-
tional cigarettes were smoked on a smoking machine according
to ISO standard 3308 (International Organization for Standardiza-
tion, 2000a). Tar, nicotine and CO were determined according to
ISO standards 4387, 10315, and 8454, respectively (International
Organization for Standardization, 1995, 2000b,c). Mainstream
smoke from EHCSS cigarettes was generated on a modiﬁed smok-
ing machine with a carousel adapted to use the EHCSS series-K
lighter. The EHCSS smoke generation conformed to ISO standard
3308; some slight technical deviations were required. The ISO
yields as declared on the cigarette packaging were as follows:
Marlboro (M6UK; 6 mg tar, 0.5 mg nicotine, and 7.0 mg CO), Philip
Morris One (PM1; 1 mg tar, 0.1 mg nicotine, and 2.0 mg CO), EHCSS-K6 (5 mg tar, 0.3 mg nicotine, and 0.6 mg CO), and EHCSS-K3 (3 mg
tar, 0.2 mg nicotine, and 0.6 mg CO).2.3. Study design and conduct
All recruited subjects (N = 175, 88 males and 87 females) com-
pleted a 7-day diary prior to check-in on Day -2 (Fig. 1). The med-
ian daily cigarette consumption according to the 7-day diary was
used to individually determine the maximum number of cigarettes
that the subject could smoke per day during the study. On Day -2
the eligibility for study inclusion was re-conﬁrmed. All subjects
were conﬁned to the clinic from Day -2 to Day 9 under medical
supervision. Vital signs were measured and a physical examination
performed (17:00). On Day -1, vital signs (07:00 and 21:00) and a
12-lead ECG were measured (07:00) and blood samples drawn for
clinical laboratory tests. On Day 0 (baseline), assessments included
determination of biomarkers of exposure in a 24-h urine sample
(combined urine voids starting at 07:00), vital signs (07:00 and
21:00), COHb17:00 (17:00), and plasma cotinine (COT-P17:00;
17:00). One hundred and sixty subjects (80 males and 80 females)
were randomized into 1 of 5 parallel groups (EHCSS-K3, EHCSS-K6,
M6UK, and PM1 cigarettes, and no-smoking; N = 32 subjects per
group) using a stratiﬁcation based on gender and median daily cig-
arette consumption (10–19 and 20–25 CPD). On randomization,
subjects continuing to smoke CC (M6UK or PM1) were ‘blind’ to
the identity of the test cigarettes. Subjects smoking EHCSS were
blind to the tar and nicotine delivery of the test cigarette. Non-ran-
domized subjects were released from the study center after com-
pleting all scheduled assessments. Subjects withdrawing from
the study or those removed by the Investigator after baseline were
not replaced. From Day 1 through Day 8, subjects participated in
their assigned study groups. Assessments included determination
of biomarkers of exposure in 24-h urine samples (starting at
07:00), vital signs (07:00 and 21:00), and determination of
COHb17:00 and COT-P17:00 (17:00). On Day 9 (end of study), vital
signs, ECG, clinical laboratory tests, and a physical examination
were performed at 07:00 prior to release of subjects from the study
center.
On Day -2 through Day 0, subjects were only permitted to smoke
the M6UK cigarette, on Day 1 through Day 8 subjects smoked their
randomized study cigarette or stopped smoking if they were ran-
domized to the no-smoking group. M6UK and PM1 cigarettes were
lit using a blue ﬂame gas lighter. EHCSS-K3 and EHCSS-K6 ciga-
rettes were smoked using the EHCSS heater (Werley et al., 2008).
To ensure study integrity, all M6UK and PM1 cigarette butts and
smoked EHCSS-K3 and EHCSS-K6 cigarettes were collected. During
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nated smoking times from 07:30 to 23:00 and subjects were not
encouraged to smoke at any time during the study. All subjects re-
ceived a dietician-designed low-mutagen diet (Smith et al., 1996),
water was permitted ad libitum and consumption of caffeinated
beverages (150 ml) allowed with meals or snacks. Identical menus
were served on Days -1, 4 and 7 (days preceding determination of
urinary mutagenicity), and on Days 0, 5 and 8 (days on which uri-
nary mutagenicity was determined).
The study was conducted at MDS Pharma Services, Belfast,
Northern Ireland, and was conducted in compliance with the eth-
ical principles that have their origin in the Declaration of Helsinki
and that are consistent with Good Clinical Practice (1964, and reg-
ularly amended; 1996). The study was approved by the Ofﬁce for
Research Ethics Committees in Northern Ireland.2.4. Bioanalytical methodology
All urine voided in a 24-h period on study Days 0 through Day 8
was stored refrigerated at 2–8 C on the day of urine collection, to-
tal urine volume was measured, and aliquots stored frozen at
20 C pending biomarker analysis (Table 1). Both tobacco-speciﬁc
and tobacco-related biomarkers of exposure to HPHC were deter-
mined (Hecht, 2003; Lindner et al., 2011; Schorp et al., 2012): (i)
tobacco-speciﬁc biomarkers of exposure were determined for nic-
otine (Benowitz et al., 1994) and NNK (Carmella et al., 2003), and
(ii) tobacco-related biomarkers of exposure were selected for 1,3-
butadiene (van Sittert et al., 2000), acrolein (Mascher et al.,
2001), benzene (Medeiros et al., 1997), crotonaldehyde (Scherer
et al., 2007), pyrene (Strickland et al., 1996), and o-toluidine (Rie-
del et al., 2006). All biomarkers were determined by liquid chroma-
tography–tandem mass spectrometry (LC–MS/MS) or gas
chromatography–mass spectrometry (GC–MS) using methods val-
idated according to Food and Drug Administration (FDA) Guidance
(Food and Drug Administration, 2001). Some of the instrumenta-
tion used (Table 1) differs to that reported in the original methods.
Excretion of mutagenic material towards Salmonella typhimurium
YG1024 was determined using the Ames plate incorporation assay
(Einistö et al., 1990). Blood samples for determination of COHb
were drawn in K3EDTA vacutainer tubes and measured on the
day of collection by spectrophotometry (Pojer et al., 1984). Blood
samples for determination of COT-P were drawn in sodium vacu-
tainer tubes and plasma stored at 20 C prior to analysis by LC–
MS/MS (Benowitz, 1988).Table 1
Summary of smoke constituent biomarkers of exposure, and bioanalytical methods.
Smoke constituent Biomarker
1,3-Butadiene Monohydroxybutenyl mercapturic acid (MHBMA)
Acrolein 3-Hydroxypropyl mercapturic acid (3-HPMA)
Benzene S-Phenyl mercapturic acid (S-PMA)
Carbon monoxide Carboxyhemoglobin (COHb)
Crotonaldehyde 3-Hydroxy-1-methylpropyl mercapturic acid (3-HMPMA)
Nicotine Cotinine (COT-P)
Nicotine equivalents (NEq)c
NNKb Total 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL)d
Pyrene Total 1-hydroxypyrene (1-OHP)e
o-Toluidine o-Toluidine (o-TOL)
Mutagens Salmonella mutagenicity (YG1024 with S9)
a Analytical methods abbreviated as: LC–MS/MS, liquid chromatography-tandem mas
b NNK, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone.
c Nicotine equivalents (NEq) were determined as the molar sum of nicotine, cotinine,
d Total 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) was determined as the
conjugate.
e Total 1-hydroxypyrene (1-OHP) was determined as the molar sum of 1-hydroxypyr
f NA, not applicable.All laboratory analyses were performed in a blinded manner
without knowledge of the study group assignment.
2.5. Data analysis
For data summary and statistical analysis, biomarker values be-
low the lower limit of quantiﬁcation (LLOQ) were set to zero. Expo-
sure to nicotine was analyzed based on nicotine equivalents (NEq)
excretion, calculated as the molar sum of the concentrations of nic-
otine and the ﬁvemajor nicotinemetabolites (nicotine-glucuronide,
free cotinine, cotinine-glucuronide, free trans-30-hydroxycotinine,
and trans-30-hydroxycotinine-glucuronide) in urine. Urine samples
showing signs of cytotoxicity and/or precipitatewere excluded from
the mutagenicity analysis.
Descriptive statistics were derived for each biomarker and their
changes from baseline by study group and day. Baseline compara-
bility of different study groups was examined using the non-para-
metric Kruskal–Wallis test. Changes in biomarker values (from
baseline to Day 8) within each study group were analyzed for addi-
tional descriptive purpose by paired sample t-tests (two-sided,
a = 0.05).
Differences in absolute end-of-study (Day 8) values between
EHCSS-K3 and the two conventional cigarette groups, M6UK and
PM1, were analyzed by analysis of covariance (ANCOVA) with fac-
tors study group, gender, and daily cigarette consumption and the
baseline value as covariate. Interaction terms for study group⁄gen-
der and study group⁄daily cigarette consumption were included
into the model if signiﬁcant interactions (at the a = 0.1 level) were
evident. If the global test showed a signiﬁcant difference between
study groups (at the a = 0.05 level), pairwise comparisons of
EHCSS-K3 and M6UK and PM1, respectively, were performed
according to Dunnett (one-sided at a = 0.025). Identical analysis
was also performed to compare EHCSS-K6 with M6UK and PM1.
Changes in urinary mutagenicity were analyzed using square
root-transformed data since the data was not normally distributed.
Additionally, urinary biomarkers adjusted for creatinine excretion,
and NEq adjusted by the individual number of cigarettes smoked
per day (NEqNCig) were analysed.
All statistical analyses were of an exploratory nature. Therefore,
apart from adjustment for the pairwise comparisons for each
EHCSS product with the two conventional cigarettes at biomarker
level, no further adjustment for multiplicity was done.
All statistical analyses were performed using SAS Version 8.2.
Unless otherwise stated, all analyses are reported for the intent-to-
treat population (ITT) which included all subjects who had a validMatrix Analytical methoda Lower limit of quantiﬁcation
Urine LC–MS/MS 100 pg/ml
Urine LC–MS/MS 35 ng/ml
Urine LC–MS/MS 20 pg/ml
Blood Spectrophotometry 0.3% Saturation
Urine LC–MS/MS 92 pg/ml
Plasma LC–MS/MS 1 ng/ml
Urine LC–MS/MS NAf
Urine LC–MS/MS 5 pg/ml
Urine LC–MS/MS 10 pg/ml
Urine GC–MS 25 pg/ml
Urine Ames plate incorporation assay NA
s spectrometry; and GC–MS, gas chromatography–mass spectrometry.
and trans-30-hydroxycotinine plus their respective glucuronide conjugates.
molar sum of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol and its O-glucuronide
ene and its glucuronide and sulfate conjugates.
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least one post-baseline assessment (subjects in the smoking
groups must have smoked at least one study cigarette).
2.6. Determination of sample size
In a previous unpublished study of similar design, the changes
of COHb17:00 and S-PMA were investigated in subjects usually
smoking M6UK when continuing to smoke M6UK or switching to
PM1. For both biomarkers the lower means at Day 8 were reported
for PM1. It was expected that in the EHCSS-K3 and EHCSS-K6
groups the Day 8 values for COHb17:00 and S-PMA values would
be at least 50% lower than in the PM1 group.
In order to detect a 50% difference in mean COHb17:00 and S-
PMA concentrations with a test power of at least 90%
(1  b = 0.9) by means of a two-sample t-test on the group means
between EHCSS-K3 and EHCSS-K6 and M6UK and PM1 at a signif-
icance level of a = 0.025 (one-sided), assuming a common standard
deviation of r = 2.0 for COHb17:00 and r = 2.5 for S-PMA, sample
sizes of 18 and 25 subjects per group were required.
Although 25 subjects per group would have been sufﬁcient, a
sample size of 32 subjects per group was chosen in order to have
balanced subgroups according to the stratiﬁcation by gender and
daily cigarette consumption. As all analyses were only of an explor-
atory nature, no adjustment to the sample size for multiplicity is-
sues was made.
2.7. Adverse events, medical history, and concomitant medication
Adverse events (AEs) and medical history were coded using the
Medical Dictionary for Regulatory Activities (MedDRA Version 7.0).
Medication was coded according to the World Health Organization
(WHO) Drug Reference List (WHO, 2003 quarter 4).3. Results
3.1. Demographic and other baseline characteristics
The ITT population consisted of 160 subjects (80 males and 80
females). Demographic characteristics by study group are summa-
rized in Table 2. All subjects were of Caucasian origin. The individ-
ual study groups were balanced with respect to gender and
smoking category (10–19 and 20–25 CPD) ratios. The mean subjectTable 2
Demographic summary by study group.
Variable and statistics Study groupa
M6UK EHCSS
Number (N) 32 32
Age (mean ± SD) 31.0 ± 8.3 28.4 ±
Gender (N, % of total)
Female 16 (50%) 16 (50
Male 16 (50%) 16 (50
BMIb (kg/m2, mean ± SD) 23.0 ± 2.7 23.7 ±
Duration of smoking (N years,% of total)
3 years or less 0 (0%) 1 (3.1
4–9 years 11 (34.4%) 14 (43
10–15 years 9 (28.1%) 9 (28.
16–19 years 2 (6.3%) 2 (6.3
20–25 years 4 (12.5%) 5 (5.6
More than 25 years 6 (18.8%) 1 (3.1
Fagerström Scorec (mean ± SD) 5.0 ± 2.1 5.0 ± 1
a Groups abbreviated as: EHCSS-K3, EHCSS series-K heater and EHCSS-K3 non-menth
heater and EHCSS-K6 non-menthol cigarette (5 mg tar, 0.3 mg nicotine, and 0.6 mg CO);
PM1, Phillip Morris One (1 mg tar, 0.1 mg nicotine, and 2.0 mg CO); and No-smoking, sm
b BMI, body mass index.
c The Fagerström Score was calculated as published (Heatherton et al., 1991).age was 28.7 ± 7.2 years (range: 19–50 years) and mean body mass
index (BMI) was 23.6 ± 2.9 kg/m2 (range: 18.6–30.0 kg/m2). Study
groups were found being comparable with regard to gender, age,
BMI, duration of smoking, and average daily cigarette consump-
tion. However, smokers of 10–19 CPD tended to be slightly youn-
ger than smokers of 20–25 CPD (27.5 ± 6.9 vs. 30.0 ± 7.4 years).
There was no difference in the mean FTND score between male
(mean score: 5.2 ± 1.8) and female (mean score: 5.2 ± 1.7) subjects.
FTND scores were lower for smokers of 10–19 CPD (mean score:
4.6 ± 1.7) compared to smokers of 20–25 CPD (mean score:
5.7 ± 1.7).
Clinical and laboratory assessments at baseline did not reveal
any clinically signiﬁcant abnormal values in the randomized sub-
jects. 155 subjects (79 males and 76 females) completed the study;
4 subjects withdrew for personal reasons, and one was discontin-
ued due to violation of selection criteria which only became appar-
ent on Day 3.
3.2. Cigarette consumption
The mean number of CPD at Day 0 (baseline) was similar among
the 5 study groups (Table 3). On Day 1, the ﬁrst day when subjects
smoked their respective randomized study cigarette, the mean
number of cigarettes smoked was lower in the EHCSS-K3 and
EHCSS-K6 groups compared to the M6UK and PM1 study groups.
On Day 8, the average cigarette consumption in all groups was
comparable, although slightly lower than at baseline. The compa-
rable cigarette consumption rates across all groups was predomi-
nantly due to the controlled smoking conditions which limited
the maximum number of cigarettes which could be smoked by
the subjects.
3.3. Biomarkers of exposure
At baseline no statistically signiﬁcant group differences were
found with regard to COHb17:00 and COT-P17:00 in blood, and bio-
markers of exposure to 1,3-butadiene, acrolein, crotonaldehyde,
nicotine (expressed as NEq), o-toluidine, pyrene, and excretion of
mutagenic material in 24-h urine at baseline (Table 4). Global
group differences at baseline were evident for biomarkers of expo-
sure to benzene and NNK (Kruskal–Wallis test p < 0.05). However,
the baseline difference in benzene exposure (one of the primary
endpoints of the study) was not considered to affect the validity
of the study results.-K6 EHCSS-K3 PM1 No-smoking
32 32 32
6.5 28.6 ± 8.2 28.0 ± 6.8 27.6 ± 6.0
%) 16 (50%) 16 (50%) 16 (50%)
%) 16 (50%) 16 (50%) 16 (50%)
3.0 23.7 ± 2.7 24.0 ± 3.1 23.8 ± 2.9
%) 2 (6.3%) 1 (3.1%) 1 (3.1%)
.8%) 9 (28.1%) 11 (34.4%) 15 (46.9%)
1%) 12 (37.5%) 12 (37.4%) 11 (34.4%)
%) 3 (9.4%) 3 (9.4%) 1 (3.1%)
%) 3 (9.4%) 4 (12.5%) 3 (9.4%)
%) 3 (9.4%) 1 (3.1%) 1 (3.1%)
.5 5.4 ± 1.9 5.3 ± 1.5 5.1 ± 1.9
ol cigarette (3 mg tar, 0.2 mg nicotine, and 0.6 mg CO); EHCSS-K6, EHCSS series-K
M6UK, Marlboro non-menthol cigarette (6 mg tar, 0.5 mg nicotine, and 7.0 mg CO);
oking cessation group.
Table 3
Daily cigarette consumption by study group and study day.
Study daya Study groupb
M6UK EHCSS-K6 EHCSS-K3 PM1 No-smoking
Day 0 (baseline) 17.6 ± 4.2 17.7 ± 3.4 17.9 ± 3.8 17.8 ± 3.6 17.8 ± 3.5
Day 1 17.1 ± 4.7 15.5 ± 4.8 15.9 ± 3.8 16.7 ± 3.7 0
Day 2 16.6 ± 4.6 15.3 ± 5.3 15.6 ± 3.6 16.5 ± 4.3 0
Day 3 16.6 ± 4.7 16.0 ± 4.2 16.1 ± 3.7 16.1 ± 4.4 0
Day 4 17.0 ± 4.6 16.6 ± 4.1 16.8 ± 3.9 16.9 ± 4.4 0
Day 5 16.9 ± 4.5 16.8 ± 4.3 16.9 ± 3.9 16.8 ± 3.9 0
Day 6 16.4 ± 4.6 16.3 ± 4.5 16.5 ± 4.0 17.2 ± 3.8 0
Day 7 17.1 ± 4.5 16.8 ± 4.0 17.1 ± 4.1 17.2 ± 4.4 0
Day 8 17.1 ± 4.6 16.8 ± 4.3 17.1 ± 3.9 17.2 ± 4.5 0
a At Day 0 (baseline) all groups smoked the Marlboro non-menthol cigarette (6 mg tar, 0.5 mg nicotine, and 7.0 mg CO) cigarette. On Day 1 through Day 8 groups smoked
their randomized study cigarette or stopped smoking.
b Groups abbreviated as: EHCSS-K3, EHCSS series-K heater and EHCSS-K3 non-menthol cigarette (3 mg tar, 0.2 mg nicotine, and 0.6 mg CO); EHCSS-K6, EHCSS series-K
heater and EHCSS-K6 non-menthol cigarette (5 mg tar, 0.3 mg nicotine, and 0.6 mg CO); M6UK, Marlboro non-menthol cigarette (6 mg tar, 0.5 mg nicotine, and 7.0 mg CO);
PM1, Phillip Morris One (1 mg tar, 0.1 mg nicotine, and 2.0 mg CO); and No-smoking, smoking cessation group.
1 Compensation = 1  [% Change in NEq per cigarette / % Change of cigarette ISO
nicotine yield].
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study, was reduced (p < 0.05) in the EHCSS-K3, EHCSS-K6, PM1,
and no-smoking groups at Day 8, compared to baseline (Table 4).
A statistically signiﬁcant increase of 28% (p < 0.05) in exposure to
CO and a minor decrease in exposure to benzene in the order of
5% was observed in the M6UK group at from baseline to Day 8.
Comparisons of Day 8 COHb17:00 and S-PMA levels by means of AN-
COVA showed statistically signiﬁcant lower levels in the two
EHCSS groups compared to both conventional cigarette groups.
Substantial reductions (all p < 0.05) in biomarkers of exposure
to 1,3-butadiene, acrolein, crotonaldehyde, nicotine (determined
as NEq and COT-P17:00), NNK, pyrene, and o-toluidine, as well as
excretion of mutagenic material in urine were observed in the
EHCSS-K6, EHCSS-K3, PM1, and no-smoking groups at Day 8, com-
pared to baseline. In the M6UK group, exposure to acrolein, croton-
aldehyde, pyrene and o-toluidine were reduced (p < 0.05) by
approximately 12–14% at Day 8, compared to baseline. Exposure
to 1,3-butadiene, nicotine (determined as NEq and COT-P17:00),
and NNK were similar in the M6UK group at Day 8, compared to
baseline. Excretion of mutagenic material in urine was reduced
(p < 0.05) in all groups at Day 8 compared to baseline, except for
in the M6UK group, which showed a marginal, but non-signiﬁcant
increase.
Group trends showing reduction of primary endpoints
(COHb17:00 and S-PMA) and tobacco-speciﬁc biomarkers of expo-
sure (COT-P17:00, NEq, and total NNAL) are presented in Figs. 2–6.
The observations were mainly unchanged after adjustment for
the number of cigarettes smoked per day or urinary creatinine
excretion. The largest reductions in exposure to all biomarkers
and excretion of mutagenic material in urine from baseline to
Day 8 were observed in the no-smoking group.
Comparisons of Day 8 biomarker levels by ANCOVA indicated
statistically signiﬁcant lower levels in most biomarkers in the
EHCSS-K3 and EHCSS-K6 groups when compared to either the
M6UK or PM1 study groups (Table 5). Smoking EHCSS-K3 and
EHCSS-K6 resulted in signiﬁcantly lower levels (p < 0.001) in all
biomarkers of exposure when compared to M6UK. When com-
pared to PM1, signiﬁcantly lower levels (p < 0.01 to p < 0.001) were
found for all biomarkers of exposure, except 1,3-butadiene and
acrolein (EHCSS-K3 and PM1) and acrolein and nicotine (for
EHCSS-K6 and PM1).
3.4. Safety evaluations
Fifty-three subjects (33.1%) reported at least one AE (88 AE epi-
sodes in total) after randomization. No trends related to study
groups were observed in AE reports, clinical laboratory, ECG, andphysical examinations. The most commonly reported AEs were
nervous system disorders (20 subjects: headache and dizziness)
and gastrointestinal disorders (19 subjects). The majority of AEs
were of mild intensity, except for two occasions of nausea and dys-
pepsia in one subject in the PM1 group. All AEs were judged to be
unrelated to the study cigarettes. Clinically signiﬁcant increases in
transaminase levels observed in four subjects (one subject in each
of the EHCSS-K3, EHCSS-K6, M6UK, and no-smoking groups) were
judged as unrelated to study cigarettes or procedures. A general
tendency towards decreased systolic and diastolic blood pressure
and pulse rate was observed in the EHCSS-K3, EHCSS-K6, and no-
smoking groups. There were no withdrawals due to an AE, and
no occurrence of a serious adverse event.
4. Discussion
This reported study of adult smokers in a controlled clinical
environment was conducted to evaluate changes in biomarkers
of exposure to selected cigarette smoke HPHC and excretion of
mutagenic material in urine occurring after switching from a con-
ventional lit-end non-menthol cigarette (M6UK) to one of two
EHCSS series-K non-menthol cigarettes, a conventional lit-end
non-menthol cigarette of lower tar yield (PM1), or to no-smoking.
A randomized, controlled, study design was used to minimize bias
and variability. Since it was unlikely that a single biomarker could
provide an assessment of reduction in exposure to multiple HPHC
present in cigarette smoke (Shields, 2002), a series of biomarkers of
exposure to different gas–vapor and particulate phase HPHC of cig-
arette smoke were investigated (Table 1). Cigarette smoke HPHC
were selected based on the availability of validated methods of
analysis for the respective biomarkers of exposure. Controlled
‘switching’ was used to maintain a fairly constant number of ciga-
rettes smoked per day (Table 3) and to minimize the effects of
compensation on switching to smoke a cigarette of lower tar and
nicotine yield (Scherer, 1999). Based on the excretion of NEq per
cigarette smoked on Day 8 compared to baseline (Table 5), subjects
switching from the M6UK cigarette to smoke the PM1 cigarette
showed an average compensation of 57% of the difference in nico-
tine yield.1 Compensation was negligible in subjects who switched
to smoke either the EHCSS-K3 or the EHCSS-K6 cigarette (1% and
4%, respectively). Similarly, Japanese smokers who switch from
smoking the Japanese Marlboro cigarette (6 mg tar, 0.5 mg nicotine,
and 7.0 mg CO, ISO methods) to use the EHCSS series-K heater and
EHCSS-K3 or EHCSS-K6 cigarettes also showed negligible compensa-
Table 4
Mean absolute biomarker levels and percentage change from baseline (Day 0) to Day 8 per study group.
Smoke constituent biomarkera,b Study groupc
M6UK EHCSS-K6 EHCSS-K3 PM1 No-smoking
COHb17:00 (%)§
Day 0 4.55 ± 1.46 4.57 ± 1.55 4.51 ± 1.47 4.72 ± 1.15 4.41 ± 1.38
Day 8 5.65 ± 1.80 1.36 ± 0.96 1.85 ± 1.35 4.09 ± 1.69 0.45 ± 0.25
Percentage change 27.9 ± 30.2%* 70.1 ± 16.7%* 60.4 ± 22.9%* 14.6 ± 24.1%* 89.1 ± 6.2%*
S-PMA (lg/24 h)§
Day 0 6.72 ± 3.25 5.49 ± 4.19 7.05 ± 3.88 5.30 ± 3.50 4.72 ± 3.43
Day 8 6.24 ± 2.90 0.86 ± 0.81 1.26 ± 1.26 3.86 ± 2.88 0.22 ± 0.08
Percentage change 4.8 ± 22.7%* 79.4 ± 14.6%* 83.1 ± 9.2%* 27.9 ± 17.4%* 93.1 ± 5.4%*
NEq (mg/24 h)
Day 0 14.25 ± 6.72 16.38 ± 8.29 16.46 ± 5.36 15.45 ± 6.12 14.39 ± 4.62
Day 8 13.07 ± 5.83 8.63 ± 5.42 6.48 ± 3.83 9.32 ± 4.72 0.00 ± 0.01
Percentage change 1.6 ± 37.3% 43.8 ± 31.1%* 60.9 ± 17.3%* 38.5 ± 19.0%* 100.0 ± 0.1%*
COT-P17:00 (ng/ml)
Day 0 234.9 ± 83.3 247.7 ± 85.2 272.0 ± 97.1 265.3 ± 103.8 268.2 ± 117.0
Day 8 234.3 ± 92.0 158.3 ± 73.1 125.0 ± 62.4 186.1 ± 94.5 0.00 ± 0.00
Percentage change 0.2 ± 29.0% 36.5 ± 24.0%* 53.9 ± 16.8%* 30.6 ± 18.4%* 100.0 ± 0.0%*
MHBMA (lg/24 h)
Day 0 5.69 ± 3.44 4.70 ± 4.77 5.23 ± 3.35 4.52 ± 3.27 3.75 ± 3.15
Day 8 5.11 ± 2.80 1.54 ± 1.52 2.63 ± 2.78 2.85 ± 2.14 0.27 ± 0.14
Percentage change 4.1 ± 29.4% 53.8 ± 32.5%* 54.4 ± 25.7%* 34.1 ± 17.2%* 77.1 ± 31.4%*
3-HPMA (mg/24 h)
Day 0 2.12 ± 0.79 2.04 ± 0.92 2.02 ± 1.00 2.15 ± 0.76 1.91 ± 0.74
Day 8 1.83 ± 0.79 1.28 ± 0.87 1.15 ± 0.74 1.30 ± 0.63 0.48 ± 0.23
Percentage change 13.6 ± 20.0%* 35.5 ± 29.2%* 41.2 ± 26.6%* 39.4 ± 17.5%* 72.2 ± 13.8%*
3-HMPMA (mg/24 h)
Day 0 6.15 ± 1.92 5.69 ± 2.06 5.85 ± 2.15 5.68 ± 1.82 6.03 ± 2.05
Day 8 5.15 ± 1.73 2.62 ± 1.29 2.59 ± 1.90 4.45 ± 1.74 1.74 ± 0.71
Percentage change 13.6 ± 26.6%* 52.8 ± 20.4%* 54.8 ± 23.2%* 21.6 ± 24.5%* 68.4 ± 14.9%*
Total NNAL (ng/24 h)
Day 0 295.2 ± 110.1 225.9 ± 121.7 257.0 ± 113.4 290.6 ± 149.2 231.0 ± 112.8
Day 8 293.6 ± 126.8 100.6 ± 68.8 104.3 ± 55.3 230.3 ± 114.6 59.2 ± 31.4
Percentage change 0.5 ± 25.0% 55.2 ± 18.5%* 60.1 ± 11.0%* 18.9 ± 19.8%* 72.2 ± 18.0%*
Total 1-OHP (ng/24 h)
Day 0 213.9 ± 65.6 206.4 ± 116.8 210.7 ± 69.8 253.2 ± 144.6 191.4 ± 68.8
Day 8 181.6 ± 60.3 71.9 ± 38.8 73.1 ± 30.4 152.9 ± 74.7 75.1 ± 54.2
Percentage change 14.0 ± 21.1%* 63.2 ± 17.5%* 64.0 ± 14.7%* 35.1 ± 22.7%* 55.4 ± 45.0%*
o-TOL (ng/24 h)
Day 0 154.7 ± 46.8 148.7 ± 63.9 148.4 ± 48.5 161.1 ± 61.5 169.8 ± 79.2
Day 8 135.0 ± 45.4 58.0 ± 58.0 49.3 ± 26.1 99.5 ± 40.1 47.6 ± 24.4
Percentage change 11.9 ± 18.7%* 61.7 ± 22.5%* 66.2 ± 13.7%* 37.9 ± 13.1%* 70.9 ± 13.0%*
Mutagenicity (rev/24 h)d
Day 0 38449 ± 16626 37176 ± 23884 38699 ± 18131 35568 ± 17447 36228 ± 16848
Day 8 41873 ± 21804 11624 ± 10719 14123 ± 11213 22384 ± 13582 6131 ± 6121
Percentage change 14.7 ± 43.9% 67.8 ± 20.9%* 66.9 ± 13.8%* 33.9 ± 28.8%* 81.9 ± 16.9%*
a Smoke constituent biomarkers abbreviated as: 1-OHP, 1-hydroxypyrene; 3-HMPMA, 3-hydroxy-1-methylpropyl mercapturic acid; 3-HPMA, 3-hydroxypropyl mercap-
turic acid; COHb17:00, carboxyhemoglobin at 17:00; COT-P17:00, plasma cotinine at 17:00; MHBMA, monohydroxybutenyl mercapturic acid; NEq, nicotine equivalents; NNAL,
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol; S-PMA, S-phenyl mercapturic acid; and o-TOL, o-toluidine.
b At Day 0 (baseline) all groups smoked the M6UK cigarette. On Day 1 through Day 8 groups smoked their randomized study cigarette or stopped smoking.
c Groups abbreviated as: EHCSS-K3, EHCSS series-K heater and EHCSS-K3 non-menthol cigarette (3 mg tar, 0.2 mg nicotine, and 0.6 mg CO); EHCSS-K6, EHCSS series-K
heater and EHCSS-K6 non-menthol cigarette (5 mg tar, 0.3 mg nicotine, and 0.6 mg CO); M6UK, Marlboro non-menthol cigarette (6 mg tar, 0.5 mg nicotine, and 7.0 mg CO);
PM1, Phillip Morris One (1 mg tar, 0.1 mg nicotine, and 2.0 mg CO); and No-smoking, smoking cessation group.
d Rev, revertants.
§ Primary objective.
* Signiﬁcant change within group from Day 0 to Day 8 (p < 0.05, p-value from two-sided paired sample t-test).
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tively) (Tricker et al., 2012a).
The observed reductions in COHb17:00, a primary endpoint of
study, from baseline to Day 8 (Table 4) are consistent with other
studies investigating reductions in exposure to CO in smokers
who switched to use previous generations of the EHCSS heater
and smoke EHCSS non-menthol cigarettes (Buchhalter and Eissen-
berg, 2000; Buchhalter et al., 2001; Hughes and Keely, 2004;
Roethig et al., 2005, 2007) and to use of the EHCSS series-K heater
and EHCSS-K3 or EHCSS-K6 cigarettes (Frost-Pineda et al., 2008a;Tricker et al., 2012a,b). The observed reduction in exposure to ben-
zene, the second primary endpoint, are also consistent with obser-
vations made in similar studies evaluating the EHCSS series-K
heater and non-menthol EHCSS-K6 cigarette (Frost-Pineda et al.,
2008a; Tricker et al., 2012a,b). Similar reductions in both primary
endpoints have been observed in smokers who switched from a
lit-end menthol cigarette to smoke a series-K menthol cigarette
(Tricker et al., 2012c).
Substantial decreases in exposure to nicotine and NNK (both
p < 0.05) were observed in the EHCSS-K3, EHCSS-K6, PM1, and
Fig. 2. Percentage carboxyhemoglobin saturation (% COHb17:00) by group and study day.
Fig. 3. S-Phenyl mercapturic acid (lg/24 h urine) by study group and study day.
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to baseline. The reductions in exposure to nicotine, determined as
NEq excretion in urine, were conﬁrmed by measurement of COT-
P17:00 (Table 4). In addition, several selected non-speciﬁc tobac-
co-related biomarkers were used to determine exposure to other
cigarette smoke HPHC. These biomarkers of exposure to 1,3-buta-
diene, acrolein, crotonaldehyde, pyrene, and o-toluidine were also
substantially decreased (all p < 0.05) in the EHCSS-K3, EHCSS-K6,
PM1, and no-smoking groups at Day 8, compared to baseline. The
observed reductions in exposure to these cigarette smoke HPHC
are similar to other studies using the EHCSS series-K heater and
EHCSS-K3 or EHCSS-K6 non-menthol cigarettes (Frost-Pineda
et al., 2008a; Tricker et al., 2012a,b) or the series-K menthol ciga-
rette (Tricker et al., 2012c).
Excretion of mutagenic material in urine, detected using tester
strain Salmonella typhimurium YG1024 (Einistö et al., 1990), was
substantially decreased (p < 0.05) in the EHCSS-K3, EHCSS-K6,
PM1, and no-smoking groups at Day 8, compared to baseline (Ta-
ble 4). Similar observations have been reported in previous studies
using earlier generations of the EHCSS heater and EHCSS non-men-thol cigarettes (Roethig et al., 2005, 2007) and the third-generation
EHCSS series-K heater and non-menthol EHCSS-K6 cigarette (Frost-
Pineda et al., 2008a; Tricker et al., 2012a,b). Salmonella typhimuri-
um YG1024, an O-acetyltransferase-overproducing derivative of
tester strain TA98, is sensitive to the mutagenic activity of aro-
matic amino, hydroxylamino, and nitro compounds present in ur-
ine (Einistö et al., 1990). o-Toluidine was selected as a
representative aromatic amino compound present in mainstream
tobacco smoke, and a substantial reduction (p < 0.05) in exposure
to this HPHC was determined in all study groups. Despite the use
of dietary control to reduce exposure to mutagens present in the
diet, the increase in excretion of mutagenic material in the
M6UK group at Day 8, compared to baseline, cannot be explained.
Comparisons of COHb17:00, biomarkers of exposure to 1,3-buta-
diene, acrolein, benzene, crotonaldehyde, nicotine (determined as
NEq and COT-P17:00), NNK, pyrene, and o-toluidine, and excretion
of mutagenic material in urine at Day 8 between the EHCSS-K6
and M6UK groups, and between the EHCSS-K3 and M6UK groups,
showed statistically signiﬁcant between-group differences
(p < 0.001), with lower values for the EHCSS-K6 and EHCSS-K3
Fig. 4. Nicotine equivalents (mg/24 h urine) by study group and study day.
Fig. 5. Cotinine (ng/ml plasma) by study group and study day.
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sure to 1,3-butadiene, acrolein, benzene, crotonaldehyde, NNK,
pyrene, and o-toluidine, and excretion of mutagenic material in ur-
ine at Day 8 between the EHCSS-K6 and PM1 groups showed sta-
tistically signiﬁcant between-group differences (p < 0.001), with
lower values for the EHCSS-K6 group, while differences in bio-
markers of exposure to nicotine (determined as NEq and COT-
P17:00) failed to reach statistical signiﬁcance. Comparisons of
COHb17:00, biomarkers of exposure to benzene, crotonaldehyde,
nicotine (determined as NEq and COT-P17:00), NNK, pyrene, and
o-toluidine, and excretion of mutagenic material in urine at Day
8 between the EHCSS-K3 and PM1 groups showed statistically sig-
niﬁcant between-group differences (p < 0.001), with lower values
for the EHCSS-K3 group, while differences in biomarkers of expo-
sure to acrolein and 1,3-butadiene failed to reach statistical
signiﬁcance.
It should be noted that there are some potential limitations to
the present study design (Schorp et al., 2012); in particular, the
short-term conﬁnement and the limited number of cigarettes
smoked by each subject. Despite these limitations, statistically sig-niﬁcant changes in biomarkers of exposure to cigarette smoke
HPHC were detected (Table 4). However, the results of this study
cannot be extrapolated to predict the long-term effects of
switching from a conventional lit-end non-menthol cigarette to
using the EHCSS series-K heater and smoking EHCSS series-K
non-menthol cigarettes as unconﬁned studies performed over a
longer timeframe indicate that increased consumption of EHCSS
cigarettes may occur (Frost-Pineda et al., 2008b; Martin Leroy
et al., 2012).
In summary, the current study shows strong mean reductions in
uptake of selected HPHC in cigarette smoke and excretion of muta-
genic material in urine from baseline to Day 8 in M6UK non-men-
thol cigarette smokers who switch to smoking either the EHCSS-K3
or the EHCSS-K6 series-K non-menthol cigarette (41.2 ± 26.6% to
66.9 ± 13.8% and 35.5 ± 29.2% to 79.4 ± 14.6%, respectively).
Smokers who switch to smoke PM1, a conventional lit-end non-
menthol cigarette representative of the low-tar cigarette market,
showed smaller reductions (14.6 ± 24.1% to 39.4 ± 17.5%). The
largest mean reductions (55.4 ± 45.0% to 100.0 ± 0.0%) occurred
in smokers who stopped smoking.
Fig. 6. Total NNAL (ng/24 h urine) by study group and study day. Determinations made on each day for the no-smoking group, and Days 0, 5, and 8 for the smoking groups.
Table 5
Comparison between study cigarettes by ANCOVA (baseline-adjusted means on Day 8).
Smoke constituent biomarkera Comparisonb,c
EHCSS-K6 vs. M6UK EHCSS-K6 vs. PM1 EHCSS-K3 vs. M6UK EHCSS-K3 vs. PM1
COHb17:00 (%)§ 4.33 (0.27)⁄⁄⁄ 2.67 (0.27)⁄⁄⁄ 3.74 (0.28)⁄⁄⁄ 0.27 (0.28)⁄⁄⁄
S-PMA (lg/24 h)§ 4.83 (0.44)⁄⁄⁄ 3.08 (0.44)⁄⁄⁄ 5.18 (0.37)⁄⁄⁄ 3.56 (0.38)⁄⁄⁄
NEq (mg/24 h) 5.44 (1.09)⁄⁄⁄ 1.20 (1.10) 7.57 (0.91)⁄⁄⁄ 3.18 (0.92)⁄⁄⁄
COT-P17:00 (ng/ml) 0.09 (0.01)⁄⁄⁄ 0.02 (0.01) 0.13 (0.01)⁄⁄⁄ 0.06 (0.01)⁄⁄⁄
MHBMA (lg/24 h) 3.29 (0.41)⁄⁄⁄ 1.41 (0.42)⁄⁄⁄ 2.19 (0.33)⁄⁄⁄ 0.62 (0.33)
3-HPMA (mg/24 h) 0.52 (0.14)⁄⁄⁄ 0.03 (0.14) 0.58 (0.12)⁄⁄⁄ 0.03 (0.12)
3-HMPMA (mg/24 h) 2.35 (0.31)⁄⁄⁄ 1.78 (0.32)⁄⁄⁄ 2.34 (0.35)⁄⁄⁄ 1.81 (0.36)⁄⁄⁄
Total NNAL (ng/24 h) 0.15 (0.02)⁄⁄⁄ 0.09 (0.02)⁄⁄⁄ 0.17 (0.01)⁄⁄⁄ 0.10 (0.01)⁄⁄⁄
Total 1-OHP (ng/24 h) 0.11 (0.01)⁄⁄⁄ 0.08 (0.01)⁄⁄⁄ 0.11 (0.01)⁄⁄⁄ 0.08 (0.01)⁄⁄⁄
o-TOL (ng/24 h) 0.07 (0.01)⁄⁄⁄ 0.03 (0.01)⁄⁄⁄ 0.08 (0.01)⁄⁄⁄ 0.04 (0.01)⁄⁄⁄
Mutagenicity (rev/24 h)d 29845.9 (3329.4)⁄⁄⁄ 12103.7 (3451.3)⁄⁄⁄ 28283.7 (3162.7)⁄⁄⁄ 10817.7 (3290.1)⁄⁄
a Smoke constituent biomarkers abbreviated as: 1-OHP, 1-hydroxypyrene; 3-HMPMA, 3-hydroxy-1-methylpropyl mercapturic acid; 3-HPMA, 3-hydroxypropyl mercap-
turic acid; COHb17:00, carboxyhemoglobin at 17:00; COT-P17:00, plasma cotinine at 17:00; MHBMA, monohydroxybutenyl mercapturic acid; NEq, nicotine equivalents; NNAL,
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol; S-PMA, S-phenyl mercapturic acid; and o-TOL, o-toluidine.
b Least squares mean (SE) and Bonferoni-corrected p-value according to Dunnett: *, p < 0.05; **, p < 0.01; ***, p < 0.001.
c Study cigarettes abbreviated as: EHCSS-K3, EHCSS series-K heater and EHCSS-K3 non-menthol cigarette (3 mg tar, 0.2 mg nicotine, and 0.6 mg CO); EHCSS-K6, EHCSS
series-K heater and EHCSS-K6 non-menthol cigarette (5 mg tar, 0.3 mg nicotine, and 0.6 mg CO); M6UK, Marlboro non-menthol cigarette (6 mg tar, 0.5 mg nicotine, and
7.0 mg CO); and PM1, Phillip Morris One (1 mg tar, 0.1 mg nicotine, and 2.0 mg CO).
d Rev, revertants.
§ Primary objective.
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